MedTrace Logo

The Effect of Esomeprazole on Type 2 Diabetes

NCT03598738 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-07-26

No results posted yet for this study

Summary

The investigators aimed to prospectively investigate the effects of esomeprazole on glycaemic control in patients with type 2 diabetes mellitus. The investigators also aimed to associate this effect with gastrin levels. Thirty-two type 2 diabetes mellitus objects were recruited into intervention (n=16) and control (n=16) groups. The participants in the intervention group were prescribed 40 mg of esomeprazole treatment for three months. At the beginning of the study and at month 3, HbA1c level (%) and gastrin levels (pmol/L) of participants were assessed. Then the baseline and 3rd month data of groups were compared.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Esomeprazole 40mg

Esomeprazole 40mg oral tablet, once a day

Sponsors & Collaborators

  • Baskent University Ankara Hospital

    lead OTHER

Principal Investigators

  • Yusuf Bozkuş, Assist Prof · Başkent University Endocrinolgy Dep

  • Neslihan Başçıl Tütüncü, Prof · Başkent University Endocrinolgy Dep

  • Özlem Turhan İyidir, Assoc Prof · Başkent University Endocrinolgy Dep

  • Umut Mousa, Dr · Başkent University Endocrinolgy Dep

  • Nazlı Kırnap, Dr · Başkent University Endocrinolgy Dep

  • Canan Çiçek Demir, Dr · Başkent University Endocrinolgy Dep

  • Aslı Nar, Assoc Prof · Başkent University Endocrinolgy Dep

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
47 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-01
Primary Completion
2017-12-01
Completion
2017-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03598738 on ClinicalTrials.gov